{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:22:22Z","timestamp":1774642942668,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1007\/s11940-000-0008-z","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T17:43:56Z","timestamp":1180979036000},"page":"263-273","source":"Crossref","is-referenced-by-count":18,"title":["Depression in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"2","author":[{"given":"Irene H.","family":"Richard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archneur.1992.00530270125028","volume":"49","author":"G Dooneief","year":"1992","unstructured":"Dooneief G, Mirabello E, Bell K, et al.: An estimate of the incidence of depression in idiopathic Parkinson\u2019s disease. Arch Neurol 1992, 49:305\u2013307.","journal-title":"Arch Neurol"},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s004150050131","volume":"244","author":"CY Liu","year":"1997","unstructured":"Liu CY, Wang SJ, Fuh JL, et al.: The correlation of depression with functional activity in Parkinson\u2019s disease. J Neurol 1997, 244:493\u2013498.","journal-title":"J Neurol"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/jnp.7.3.281","volume":"7","author":"T Klaassen","year":"1995","unstructured":"Klaassen T, Verhey FRJ, Sneijders GH, et al.: Treatment of depression in Parkinson\u2019s disease. A meta-analysis. J Neuropsychiatry Clin Neurosci 1995, 7:281\u2013286.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.49.4.1168","volume":"49","author":"IH Richard","year":"1997","unstructured":"Richard IH, Kurlan R: A survey of antidepressant usage in Parkinson\u2019s disease. Neurology 1997, 49:1168\u20131170.","journal-title":"Neurology"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00019442-199700520-00002","volume":"5","author":"LS Schneider","year":"1997","unstructured":"Schneider LS, Small GW, Hamilton SH, et al.: Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry 1997, 5:97\u2013106.","journal-title":"Am J Geriatr Psychiatry"},{"key":"8_CR6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","volume":"148","author":"H Sternbach","year":"1991","unstructured":"Sternbach H: The serotonin syndrome. Am J Psychiatry 1991, 148:705\u2013713.","journal-title":"Am J Psychiatry"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/070674379003500632","volume":"35","author":"O Suchowersky","year":"1990","unstructured":"Suchowersky O, deVries JD: Interaction of fluoxetine and selegiline. Can J Psychiatry 1990, 35:571\u2013572.","journal-title":"Can J Psychiatry"},{"key":"8_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S031716710004124X","volume":"21","author":"CH Waters","year":"1994","unstructured":"Waters CH: Fluoxetine and selegiline\u2014lack of significant interaction. Can J Neurol Sci 1994, 21:259\u2013261.","journal-title":"Can J Neurol Sci"},{"key":"8_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/106002809402800324","volume":"28","author":"SC Toyama","year":"1994","unstructured":"Toyama SC, Iocono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994, 28:405\u2013406.","journal-title":"Ann Pharmacother"},{"key":"8_CR10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00002826-199710000-00006","volume":"20","author":"K Laine","year":"1997","unstructured":"Laine K, Anttila M, Heinonen E, et al.: Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997, 20:419\u2013433.","journal-title":"Clin Neuropharmacol"},{"key":"8_CR11","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","volume":"48","author":"IH Richard","year":"1997","unstructured":"Richard IH, Kurlan R, Tanner C, et al.: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease. Neurology 1997, 48:1070\u20131077. This article provides 1) an overview of the serotonin syndrome, 2) details regarding the reports of adverse events in patients with PD who used antidepressants in combination with selegiline, and 3) the authors\u2019 interpretation of the literature and recommendations.","journal-title":"Neurology"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/mds.870120522","volume":"12","author":"RA Hauser","year":"1997","unstructured":"Hauser RA, Zesiewicz TA: Sertraline for the treatment of depression in Parkinson\u2019s disease. Mov Disord 1997, 12:756\u2013759.","journal-title":"Mov Disord"},{"key":"8_CR13","first-page":"12","volume":"1","author":"LM Shulman","year":"1996","unstructured":"Shulman LM, Singer C, Liefert R, et al.: Therapeutic effects of sertraline (Zoloft) in patients with Parkinson\u2019s disease (PD) [abstract]. Mov Disord 1996, 1:12.","journal-title":"Mov Disord"},{"key":"8_CR14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1212\/WNL.42.9.1813","volume":"42","author":"EF McCance-Katz","year":"1992","unstructured":"McCance-Katz EF, Marek KL, Price LH: Serotonergic dysfunction in depression associated with Parkinson\u2019s disease. Neurology 1992, 42:1813\u20131814.","journal-title":"Neurology"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/mds.870100325","volume":"10","author":"JL Montastruc","year":"1995","unstructured":"Montastruc JL, Fabre N, Blin O: Does fluoxetine aggravate Parkinson\u2019s disease? A pilot prospective study. Mov Disord 1995, 10:355\u2013357.","journal-title":"Mov Disord"},{"key":"8_CR16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/(SICI)1099-1077(199606)11:2+<S75::AID-HUP805>3.0.CO;2-B","volume":"11","author":"BE Leonard","year":"1996","unstructured":"Leonard BE, Faherty C: SSRIs and movement disorders. Is serotonin the culprit? Hum Psychopharmacol 1996, 11(suppl):75\u201382. This article provides an overview of the literature pertaining to SSRI-induced movement disorders and a discussion of possible mechanisms.","journal-title":"Hum Psychopharmacol"},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.43.1_Part_1.211","volume":"43","author":"ENH Steur","year":"1993","unstructured":"Steur ENH: Increase of Parkinson disability after fluoxetine medication. Neurology 1993, 43:211\u2013213.","journal-title":"Neurology"},{"key":"8_CR18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/mds.870110517","volume":"11","author":"JA Simons","year":"1996","unstructured":"Simons JA: Fluoxetine in Parkinson\u2019s disease. Mov Disord 1996, 11:581\u2013582.","journal-title":"Mov Disord"},{"key":"8_CR19","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1212\/WNL.44.12.2406","volume":"44","author":"FJ Jimenez-Jimenez","year":"1994","unstructured":"Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, et al.: Parkinsonism exacerbated by paroxetine. Neurology 1994, 44:2406.","journal-title":"Neurology"},{"key":"8_CR20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hup.470090607","volume":"9","author":"G Meco","year":"1994","unstructured":"Meco G, Bonifati V, Fabrizio E: Worsening of parkinsonism with fluvoxamine: two cases. Hum Psychopharmacol 1994, 9:439\u2013441.","journal-title":"Hum Psychopharmacol"},{"key":"8_CR21","first-page":"1352","volume":"146","author":"TM Brod","year":"1989","unstructured":"Brod TM: Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989, 146:1352\u20131353.","journal-title":"Am J Psychiatry"},{"key":"8_CR22","first-page":"278","volume":"53","author":"CF Caley","year":"1992","unstructured":"Caley CF, Friedman JH: Does fluoxetine exacerbate Parkinson\u2019s disease? J Clin Psychiatry 1992, 53:278\u2013282.","journal-title":"J Clin Psychiatry"},{"key":"8_CR23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1531-8257(199901)14:1<155::AID-MDS1026>3.0.CO;2-Z","volume":"14","author":"IH Richard","year":"1999","unstructured":"Richard IH, Maughan A, Kurlan R: Do serotonin reuptake inhibitor antidepressants worsen Parkinson\u2019s disease? A retrospective case series. Mov Disord 1999, 14:155\u2013157.","journal-title":"Mov Disord"},{"key":"8_CR24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1192\/bjp.164.5.665","volume":"164","author":"B Jonsson","year":"1994","unstructured":"Jonsson B, Bebbington PE: What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994, 164:665\u2013673.","journal-title":"Br J Psychiatry"},{"key":"8_CR25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/bmj.2.5452.33","volume":"2","author":"RR Strong","year":"1965","unstructured":"Strong RR: Imipramine in treatment of parkinsonism: a double blind placebo study. Br Med J 1965, 2:33\u201334.","journal-title":"Br Med J"},{"key":"8_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0404.1969.tb01224.x","volume":"45","author":"L Laitinen","year":"1969","unstructured":"Laitinen L: Desipramine in treatment of Parkinson\u2019s disease. Acta Neurol Scand 1969, 45:109\u2013113.","journal-title":"Acta Neurol Scand"},{"key":"8_CR27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0404.1980.tb03028.x","volume":"62","author":"J Anderson","year":"1980","unstructured":"Anderson J, Aabro E, Gulmann N: Anti-depressive treatment in Parkinson\u2019s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson\u2019s disease treated with L-dopa. Acta Neurol Scand 1980, 62:210\u2013219.","journal-title":"Acta Neurol Scand"},{"key":"8_CR28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1212\/WNL.34.8.1092","volume":"34","author":"CG Goetz","year":"1984","unstructured":"Goetz CG, Tanner CM, Klawans HL: Bupropion in Parkinson\u2019s disease. Neurology 1984, 34:1092\u20131094.","journal-title":"Neurology"},{"key":"8_CR29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-7091-6499-0_6","volume":"52","author":"S Fahn","year":"1998","unstructured":"Fahn S, Chouinard S: Experience with tranylcypromine in early Parkinson\u2019s disease. J Neural Transm 1998, 52:49\u201361.","journal-title":"J Neural Transm"},{"key":"8_CR30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/jnnp.63.4.547","volume":"63","author":"EN Steur","year":"1997","unstructured":"Steur EN, Ballering LA: Moclobemide and selegiline in the treatment of depression in Parkinson\u2019s disease [letter]. J Neurol Neurosurg Psychiatry 1997, 63:547.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8_CR31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0009-9236(96)90115-0","volume":"59","author":"A Illi","year":"1996","unstructured":"Illi A, Sundberg S, Ojala-Karlsson P, et al.: Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects of hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996, 59:450\u2013457.","journal-title":"Clin Pharmacol Ther"},{"key":"8_CR32","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/00002826-199720001-00006","volume":"20","author":"A Szegedi","year":"1997","unstructured":"Szegedi A, Hillert A, Wetzel H, et al.: Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 1997, 20:S36-S45.","journal-title":"Clin Neuropharmacol"},{"key":"8_CR33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2007-979191","volume":"32","author":"TJ Huber","year":"1999","unstructured":"Huber TJ, Dietrich DE, Emrich HM: Possible use of amantadine in depression. Pharmacopsychiatry 1999, 32:47\u201355.","journal-title":"Pharmacopsychiatry"},{"key":"8_CR34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/archfami.7.3.274","volume":"7","author":"K DasGupta","year":"1998","unstructured":"DasGupta K: Treatment of depression in elderly patients. Recent advances. Arch Fam Med 1998, 7:274\u2013280. This is a very straightforward and practical article that provides an overview of treatment approaches to depression in the elderly.","journal-title":"Arch Fam Med"},{"key":"8_CR35","first-page":"274","volume":"13","author":"D Aarsland","year":"1997","unstructured":"Aarsland D, Larsen JP, Waage O, Langeveld JH: Maintenance electroconvulsive therapy for Parkinson\u2019s disease. Convuls Ther 1997, 13:274\u2013277.","journal-title":"Convuls Ther"},{"key":"8_CR36","first-page":"47","volume":"7","author":"MD Miller","year":"1997","unstructured":"Miller MD, Wolfson L, Frank E, et al.: Using interpersonal psychotherapy (IPT) in a combined psychotherapy\/ medication research protocol with depressed elders. A descriptive report of case vignettes. J Psychother 1997, 7:47\u201355.","journal-title":"J Psychother"},{"key":"8_CR37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1176\/jnp.8.4.373","volume":"8","author":"MS George","year":"1996","unstructured":"George MS, Wassermann EM, Post RM: Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. J Neuropsychiatry Clin Neurosci 1996, 8:373\u2013382. This article provides an overview of the relatively new technique known as transcranial magnetic stimulation, which may have relevance to PD and depression.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"8_CR38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/1531-8257(199901)14:1<157::AID-MDS1027>3.0.CO;2-U","volume":"14","author":"R Kumar","year":"1999","unstructured":"Kumar R, Chen R, Ashby P: Safety of transcranial magnetic stimulation in patients with implanted deep brain stimulators. Mov Disord 1999, 14:157\u2013185.","journal-title":"Mov Disord"},{"key":"8_CR39","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1176\/ajp.154.12.1752","volume":"154","author":"MS George","year":"1997","unstructured":"George MS, Wassermann EM, Kimbrell TA, et al.: Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am J Psychiatry 1997, 154:1752\u20131756.","journal-title":"Am J Psychiatry"},{"key":"8_CR40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.156.4.669","volume":"156","author":"JA Mattes","year":"1999","unstructured":"Mattes JA: Mood improvement from transcranial magnetic stimulation [letter]. Am J Psychiatry 1999, 156:669.","journal-title":"Am J Psychiatry"},{"key":"8_CR41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archpsyc.56.4.315","volume":"56","author":"E Klein","year":"1999","unstructured":"Klein E, Kreinin I, Chistyakov A, et al.: Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a doubleblind controlled study. Arch Gen Psychiatry 1999, 56:315\u2013320.","journal-title":"Arch Gen Psychiatry"},{"key":"8_CR42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-510X(98)00318-9","volume":"162","author":"J Mally","year":"1999","unstructured":"Mally J, Stone TW: Improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci 1999, 162:179\u2013184.","journal-title":"J Neurol Sci"},{"key":"8_CR43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00001756-199902250-00027","volume":"10","author":"HR Siebner","year":"1999","unstructured":"Siebner HR, Mentschel C, Auer C, Conrad B: Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson\u2019s disease. Neuroreport 1999, 10:589\u2013594.","journal-title":"Neuroreport"},{"key":"8_CR44","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.52.4.768","volume":"52","author":"MB Ghabra","year":"1999","unstructured":"Ghabra MB, Hallett M, Wassermann EM: Simultaneous repetitive transcranial magnetic stimulation does not speed fine movement in PD. Neurology 1999, 52:768\u2013770.","journal-title":"Neurology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0008-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-000-0008-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0008-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T19:40:04Z","timestamp":1707939604000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-000-0008-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s11940-000-0008-z","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}